Decentralized Clinical Trials for Medical Devices: FDA Guidance, Hybrid Models, and Implementation Guide

Clinical Trials Are Leaving the Hospital

For decades, clinical trials for medical devices required patients to travel to investigational sites — academic hospitals, specialized clinics, or research centers — for every assessment, every follow-up, every data point. That model excluded rural populations, burdened elderly and mobility-limited participants, and produced data that reflected only the patients who could afford to show up.

Decentralized clinical trials (DCTs) change that equation. By leveraging telehealth, wearable sensors, remote monitoring, electronic consent, and local healthcare providers, DCTs move trial activities to where the patient already is — at home, at a nearby clinic, or through a mobile device. The approach is not theoretical. The global DCT market was valued at $8.8 billion in 2024 and is projected to reach $18.8 billion by 2030 at a compound annual growth rate of 13.7%, and medical device manufacturers are the fastest-growing constituency.

This guide covers the regulatory framework, operational models, technology requirements, and practical implementation steps for decentralized clinical trials in medical devices.

What Are Decentralized Clinical Trials?

A decentralized clinical trial is a clinical trial that includes decentralized elements where trial-related activities occur at locations other than traditional clinical trial sites. The FDA's September 2024 final guidance, "Conducting Clinical Trials with Decentralized Elements," establishes the regulatory framework.

Key Terminology

The FDA's Position

The FDA's final guidance makes several points clear:

• Regulatory requirements do not change based on whether a trial is decentralized. The same ICH E6 GCP standards, informed consent requirements, and data integrity expectations apply.
• The agency acknowledges that fully decentralized trials may be appropriate for investigational products with well-characterized safety profiles that do not require complex preparation, administration, or medical assessment.
• The guidance focuses on the elements of decentralization rather than classifying trials as either "DCT" or "hybrid" — a shift from the draft guidance.
• Electronic systems used in DCTs must comply with 21 CFR Part 11 requirements.

Why DCTs Matter for Medical Devices

Market Growth and Adoption

The medical device clinical trials market was valued at $16.70 billion in 2024 and is projected to reach $30.53 billion by 2034. Within this market, decentralized approaches are growing faster than any other segment:

Specific Advantages for Device Trials

DCTs align naturally with several device-specific characteristics:

• Wearable and connected devices generate continuous data streams that are captured remotely by design. Remote monitoring is not a workaround — it is the intended use case.
• Post-market surveillance and PMCF studies require long-term follow-up of patients using approved devices. Decentralized approaches reduce patient burden and improve retention over extended observation periods.
• Implantable devices benefit from remote monitoring of device performance, battery status, and patient-reported outcomes without requiring clinic visits.
• Rare disease device trials face the challenge of recruiting small, geographically dispersed patient populations. DCTs make these trials feasible by removing geographic barriers.

Measured Benefits

Industry data from trials that have adopted decentralized elements shows:

• Improved recruitment: Remote screening and eConsent reduce screen failures and accelerate enrollment timelines.
• Better retention: Reducing patient travel burden decreases dropout rates, particularly in chronic disease and long-term device studies.
• Greater diversity: DCTs enable participation from rural, elderly, and mobility-limited populations who are systematically excluded from traditional site-based trials.
• Real-world data capture: Wearable sensors and home monitoring generate continuous, real-world data that is often more representative than periodic clinic-based assessments.

Regulatory Framework

FDA Requirements

The FDA's final guidance (September 2024) applies to all clinical investigations subject to FDA oversight, including medical device IDE trials. Key regulatory requirements:

Informed Consent (21 CFR Part 50)

• Electronic consent (eConsent) is acceptable when it meets all elements of informed consent
• The eConsent process must include comprehension assessments
• Participants must be able to ask questions and receive answers in real time
• A copy of the signed consent must be provided to the participant

Investigational Device Exemptions (21 CFR Part 812)

• IDE requirements apply regardless of trial location
• Sponsors must ensure proper device accountability at all locations, including participant homes
• Shipping and handling of investigational devices must be documented and controlled
• The investigator remains responsible for all delegated activities

Electronic Records (21 CFR Part 11)

• All electronic systems used in DCTs must comply with Part 11
• Electronic signatures must be equivalent to handwritten signatures
• Audit trails must capture all changes to electronic records
• System validation documentation must be maintained

Data Integrity

• Source data from remote locations must meet the same standards as site-collected data
• Sponsors must validate that digital health technologies accurately capture clinical endpoints
• Data from wearable sensors must be verified against clinical-grade instruments where applicable

EU Framework

The EU Clinical Trials Regulation (CTR 536/2014) does not specifically address DCTs, but several provisions support decentralized elements:

• Electronic consent: Permitted under national law in most EU member states
• Remote assessments: Acceptable when validated and documented in the protocol
• Local HCPs: Can perform protocol-specified activities under the supervision of the principal investigator
• Data protection: GDPR requirements apply to all patient data collected remotely, including wearable sensor data

The EMA has signaled support for DCTs through its Accelerating Clinical Trials in the EU (ACT EU) initiative, and ICH E6(R3) GCP guidelines effective April 2026 explicitly address remote monitoring and electronic data systems.

International Harmonization

ICH E6(R3) GCP (Effective April 2026)

The revised ICH E6(R3) GCP guideline, adopted by the FDA, EMA, and Health Canada effective April 2026, represents the most significant update to clinical trial standards in two decades. Key provisions affecting DCTs:

• Explicit recognition of electronic data systems and digital health technologies as acceptable tools for clinical research
• Shift from site-centric monitoring to Critical-to-Quality (CtQ) factor-based oversight, supporting risk-based monitoring approaches
• Support for decentralized elements including telehealth, eConsent, and remote source data verification
• Updated provisions for computerized systems validation aligned with 21 CFR Part 11

Health Canada adopted ICH E6(R3) GCP effective April 1, 2026, with a six-month preparatory period. Japan's PMDA has accepted remote monitoring data in device submissions since 2024. Sponsors who design DCT protocols aligned with E6(R3) principles will be positioned for simultaneous multi-regional submissions.

Trial Design Models

Fully Decentralized Trials

All trial activities occur outside traditional investigational sites. Best suited for:

• Devices with well-characterized safety profiles
• Software-as-a-Medical-Device (SaMD) where the intervention is entirely digital
• Post-market surveillance studies and registries
• Wearable device validation studies

Requirements for fully decentralized device trials:

• The investigational device must be safely self-administered or administered by a caregiver
• No complex medical assessment should be required for device placement or activation
• Remote monitoring must provide adequate safety surveillance
• An emergency response plan must be documented for adverse events occurring at home

Hybrid Trials

Most device DCTs in 2026 use a hybrid model, combining on-site visits for critical assessments with remote follow-up:

Selective Decentralization

The most common approach in 2025-2026 is not full decentralization but selective addition of DCT elements where they reduce patient burden without compromising oversight:

1. Remote follow-up visits — Replace routine post-implant check-ins with telehealth
2. Local lab draws — Use nearby labs instead of requiring travel to the investigational site
3. eConsent with comprehension checks — Digitize the consent process with embedded assessments
4. Home delivery of study materials — Ship sensors, diaries, or study-specific supplies directly
5. Wearable-based endpoint capture — Use validated sensors for continuous data collection

Technology Requirements

Digital Health Technologies for Device Trials

Wearable Validation Requirements

When using wearable devices as clinical endpoints in a DCT:

1. Analytical validation: Demonstrate that the sensor accurately measures the physiological parameter it claims to measure (sensitivity, specificity, accuracy compared to gold standard)
2. Clinical validation: Establish that the wearable-derived measurement is clinically meaningful for the specific device trial endpoint
3. Usability validation: Confirm that participants can correctly use the device at home without clinical supervision
4. Data quality assurance: Implement automated data quality checks (wear time compliance, signal quality, artifact detection)

Cybersecurity Considerations

FDA's cybersecurity requirements (Section 524B, effective since 2023) apply to connected devices used in DCTs:

• Secure-by-design architecture for all digital health technologies
• Encryption of patient data in transit and at rest
• Multi-factor authentication for remote system access
• Incident response plans for data breaches
• SBOM documentation for all software components

Implementation Framework

Step 1: Protocol Design

Design the protocol with DCT elements integrated from the start, not bolted on afterward:

• Identify which visits can realistically be conducted remotely based on the device and clinical endpoint requirements
• Define primary and secondary endpoints that can be captured through digital health technologies
• Build in safety escalation pathways — when does a remote assessment trigger an in-person visit?
• Specify wearable validation criteria in the statistical analysis plan

Step 2: Regulatory Strategy

• File the IDE (or equivalent) with DCT elements clearly described in the protocol
• Include a Digital Health Technology Validation Plan as a protocol appendix
• Pre-engage the FDA through the Pre-Submission (Q-Submission) process for novel DCT endpoints
• Document the eConsent process for IRB review, including comprehension assessment methodology

Step 3: Technology Platform Selection

Evaluate DCT technology vendors on:

• Regulatory track record (FDA inspection history, Part 11 compliance documentation)
• Interoperability with your EDC and clinical data management systems
• Global deployment capability (languages, regulatory jurisdictions, data residency)
• Offline functionality for participants with unreliable internet access
• Data export formats compatible with your statistical analysis plan

Step 4: Site and Staff Training

• Train investigators on telehealth assessment techniques specific to your device
• Develop a DCT operations manual covering remote visit procedures, local HCP engagement, and home nursing coordination
• Create participant-facing training materials for wearable use, ePRO completion, and telehealth logistics
• Establish a help desk for participant technology issues

Step 5: Data Management and Monitoring

• Implement risk-based monitoring with centralized statistical monitoring of remote data
• Define key risk indicators (KRIs) specific to DCT elements: wearable compliance, ePRO completion rates, telehealth visit show rates
• Establish source data verification procedures for remote data (remote SDV using screen sharing, photo documentation, or local HCP attestation)
• Build automated data quality dashboards tracking endpoint completeness

Step 6: Safety Management

• Document adverse event reporting pathways for events occurring at home or at local HCP facilities
• Define medical oversight responsibilities for remote participants
• Establish 24/7 clinical support availability for participants in fully decentralized or hybrid trials
• Create a safety escalation matrix: when does a remote finding trigger an immediate in-person evaluation?

Challenges and Mitigations

Cost and Timeline Considerations

Potential Cost Savings

Decentralized elements can reduce trial costs in several areas:

• Site overhead: Fewer on-site visits mean less site staff time and facility costs
• Patient travel reimbursements: Reduced or eliminated for remote visits
• Retention: Lower dropout rates reduce the need for over-enrollment
• Monitoring: Risk-based monitoring with centralized data reduces on-site monitoring visits by 20-30%

Additional Costs

• Technology: Wearable sensors ($200-500 per participant), ePRO licenses, telehealth platform fees
• Home nursing: $150-300 per visit for home-based assessments
• Shipping logistics: $50-200 per shipment for investigational devices and supplies
• Training: Additional training for investigators, local HCPs, and participants on DCT procedures
• Validation: Wearable and DHT validation studies add upfront cost and timeline

Net Impact

Industry data suggests that well-designed hybrid trials with DCT elements achieve a 10-20% net cost reduction compared to fully traditional site-based trials, primarily driven by faster enrollment and lower dropout rates.

The Future of Device Clinical Trials

Several trends will accelerate DCT adoption in medical devices through 2027-2030:

• AI-driven trial optimization: Machine learning models that dynamically adjust DCT elements based on real-time enrollment and data quality metrics
• Digital twins: Virtual patient models that supplement clinical data with simulated outcomes, reducing the number of physical assessments needed
• Real-world evidence integration: DCT platforms that seamlessly integrate electronic health records, claims data, and registry data with trial data
• Regulatory harmonization: ICH E6(R3) and IMDRF guidance are converging toward global acceptance of decentralized trial elements
• Expanded therapeutic areas: Neurology (16.02% CAGR) and cardiology are rapidly adopting DCTs as wearable endpoints mature
• Bring Your Own Technology (BYOT): The Decentralized Trials & Research Alliance (DTRA) published a BYOT playbook in 2025, enabling clinical research sites to use their own validated eClinical systems (eSource, eConsent, eReg) within sponsor-funded trials — reducing site burden and improving operational efficiency
• Enterprise-scale adoption: Major sponsors have moved beyond pilots to portfolio-scale DCT implementation. GSK's four-year enterprise contract with Medable to power decentralized and hybrid clinical trials across its global product portfolio demonstrates enterprise commitment

Key Takeaways

1. The FDA has endorsed DCTs through its September 2024 final guidance, which explicitly recognizes telehealth, remote monitoring, local HCPs, and eConsent as acceptable trial elements.
2. Hybrid models dominate — most device trials in 2026 selectively add decentralized elements where they reduce burden without compromising safety.
3. Medical device manufacturers are the fastest-growing segment of DCT adoption, driven by wearable validation and post-market surveillance.
4. Technology validation is critical — wearables and digital endpoints must be analytically and clinically validated before they can replace traditional assessments.
5. Regulatory requirements do not change — GCP, informed consent, data integrity, and safety reporting obligations remain the same regardless of trial location.
6. The DCT market is projected to reach $18.8 billion by 2030, reflecting a fundamental shift in how clinical evidence is generated.